SurModics (SRDX) Misses Q2 EPS by 2c; Narrows Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Surmodics Reports Second Quarter Fiscal 2017 Results, Updates Fiscal 2017 Financial Guidance
April 27, 2017 7:30 AM EDTEDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2017 second quarter, ended March 31, 2017.
Second Quarter Fiscal 2017 Financial Highlights
Total Revenue of $17.5 Million, up 5% year over year; Medical Device revenue increases 10% EPS of $0.04, Non-GAAP EPS of $0.05 Narrows financial outlook for fiscal 2017"This was an excellent quarter, both in terms of our revenue performance... More
